Abstract
The antimicrobial and chemotherapeutic activities of a silver(I) glutamic acid complex with the synergistic concomitant generation of reactive oxygen species (ROS) were investigated here. The ROS generation system employed was via Fenton chemistry. The antimicrobial and chemotherapeutic activities were investigated on Staphylococcus aureus ATCC 43300 and Escherichia coli bacteria, and Vero and MCF-7 tumor cell lines, respectively. Antimicrobial activities were conducted by determining minimum inhibitory concentration (MIC), while chemotherapeutic efficacies were done by serial dilution using standard techniques to determine the half maximal inhibitory concentration (IC50). The antimicrobial and chemotherapeutic results obtained were compared with positive control drugs gentamicin, oxacillin, penicillin, streptomycin and cisplatin, a ubiquitously used platinum-based antitumor drug, and with the silver(I) glutamic acid complex and hydrogen peroxide separately. Based on MIC and IC50 values, it was determined that this synergistic approach was very effective at extremely low concentrations, especially when compared with the other drugs evaluated here. This finding might be of great significance regarding metronomic dosing when this synergistic approach is clinically implemented. Since silver at low concentrations exhibits no toxic, mutagenic and carcinogenic activities, this might offer an alternative approach for the development of safer silver-based antimicrobial and chemotherapeutic drugs, thereby reducing or even eliminating the toxicity associated with current drugs. Accordingly, the present approach might be integrated into the systemic clinical treatment of infectious diseases and cancer.
Keywords: Antimicrobial, chemotherapy, Escherichia coli, glutamic acid, MCF-7, reactive oxygen species (ROS), silver, Staphylococcus aureus, vero,
Current Medicinal Chemistry
Title:Synergistic Activities of a Silver(I) Glutamic Acid Complex and Reactive Oxygen Species (ROS): A Novel Antimicrobial and Chemotherapeutic Agent
Volume: 19 Issue: 21
Author(s): K. I. Batarseh and M. A. Smith
Affiliation:
Keywords: Antimicrobial, chemotherapy, Escherichia coli, glutamic acid, MCF-7, reactive oxygen species (ROS), silver, Staphylococcus aureus, vero,
Abstract: The antimicrobial and chemotherapeutic activities of a silver(I) glutamic acid complex with the synergistic concomitant generation of reactive oxygen species (ROS) were investigated here. The ROS generation system employed was via Fenton chemistry. The antimicrobial and chemotherapeutic activities were investigated on Staphylococcus aureus ATCC 43300 and Escherichia coli bacteria, and Vero and MCF-7 tumor cell lines, respectively. Antimicrobial activities were conducted by determining minimum inhibitory concentration (MIC), while chemotherapeutic efficacies were done by serial dilution using standard techniques to determine the half maximal inhibitory concentration (IC50). The antimicrobial and chemotherapeutic results obtained were compared with positive control drugs gentamicin, oxacillin, penicillin, streptomycin and cisplatin, a ubiquitously used platinum-based antitumor drug, and with the silver(I) glutamic acid complex and hydrogen peroxide separately. Based on MIC and IC50 values, it was determined that this synergistic approach was very effective at extremely low concentrations, especially when compared with the other drugs evaluated here. This finding might be of great significance regarding metronomic dosing when this synergistic approach is clinically implemented. Since silver at low concentrations exhibits no toxic, mutagenic and carcinogenic activities, this might offer an alternative approach for the development of safer silver-based antimicrobial and chemotherapeutic drugs, thereby reducing or even eliminating the toxicity associated with current drugs. Accordingly, the present approach might be integrated into the systemic clinical treatment of infectious diseases and cancer.
Export Options
About this article
Cite this article as:
I. Batarseh K. and A. Smith M., Synergistic Activities of a Silver(I) Glutamic Acid Complex and Reactive Oxygen Species (ROS): A Novel Antimicrobial and Chemotherapeutic Agent, Current Medicinal Chemistry 2012; 19 (21) . https://dx.doi.org/10.2174/092986712801323216
DOI https://dx.doi.org/10.2174/092986712801323216 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Infectious Disorders - Drug Targets Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Advances and Challenges in the Synthesis of Highly Oxidised Natural Phenols with Antiviral, Antioxidant and Cytotoxic Activities
Current Medicinal Chemistry Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Pgp and FLT3: Identification and Modulation of Two Proteins that Lead to Chemotherapy Resistance in Acute Myeloid Leukemia
Current Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design The Cell-Type Specificity and Endosomal Escape of Cell-Penetrating Peptides
Current Pharmaceutical Design Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry Pharmacophore Modelling as a Virtual Screening Tool for the Discovery of Small Molecule Protein-protein Interaction Inhibitors
Current Pharmaceutical Design Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Synthesis and Antiproliferative Evaluation of Spirothiadiazolopyridazine Derivatives
Letters in Drug Design & Discovery Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Kit: Molecule of Interest for the Diagnosis and Treatment of Mastocytosis and other Neoplastic Disorders
Current Cancer Drug Targets New Purine Nucleoside Analogs for Acute Lymphoblastic Leukemia
Clinical Cancer Drugs Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry